Monoclonal antibody (mAb) therapy has revolutionized cancer treatment, especially in B-cell malignancies. The cytotoxic effects of mAbs against cancer cells are mediated through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) via the fragment crystallizable (Fc) domain. To enhance these anti-tumor functions, Fc-engineering strategies have been developed. This review focuses on summarizing the advancements in Fc-engineering aimed at boosting Fc-effector function and improving the anti-tumor potency of mAbs, particularly in the context of B-cell malignancies like chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma (B-NHL), and multiple myeloma (MM).
The success of mAbs in cancer therapy stems from their ability to engage cytotoxic pathways against specific targets. Fc-engineering strategies aim to enhance these functions by modifying the Fc domain. Techniques such as glycoengineering and site-directed mutagenesis have been employed to improve FcγR and C1q binding, crucial for ADCC, ADCP, and CDC. For instance, glycoengineering approaches like afucosylation and galactosylation have shown promise in enhancing FcγR affinity, thereby increasing ADCC and ADCP. Similarly, site-directed mutagenesis has been used to introduce specific mutations that enhance FcγR and C1q binding, ultimately boosting the mAb’s anti-tumor activity.
In B-cell malignancies, CD20-targeting mAbs have been at the forefront of therapeutic development. Rituximab, the first FDA-approved mAb for cancer therapy, paved the way for subsequent advancements in targeting CD20. Glycoengineered mAbs like obinutuzumab and ublituximab have demonstrated improved clinical outcomes in CLL and B-NHL by enhancing ADCC and CDC. Fc-mutated CD20-targeting mAbs have been designed to cater to individual patient responses based on FcγRIIIa polymorphisms, highlighting the importance of personalized treatment strategies in precision medicine.
Clinical trials investigating the efficacy of Fc-engineered mAbs in B-cell malignancies are ongoing, showcasing the continuous evolution of mAb therapy. By enhancing Fc-effector functions, these engineered antibodies hold the promise of improved outcomes for patients with hematological cancers. The interplay between Fc-engineering strategies, antigen specificity, and patient genetics underscores the complexity of designing tailored therapeutic approaches. As research in this field progresses, the potential for Fc-engineered mAbs to further optimize cancer treatment regimens continues to expand.
Key Takeaways:
– Fc-engineering strategies aim to enhance the anti-tumor potency of mAbs by improving Fc-effector functions like ADCC and CDC.
– Glycoengineering and site-directed mutagenesis are key techniques used to modify the Fc domain for enhanced binding to FcγR and C1q.
– CD20-targeting mAbs, including glycoengineered and Fc-mutated variants, have shown promising results in B-cell malignancies, emphasizing the importance of personalized treatment approaches.
– Ongoing clinical trials are evaluating the efficacy of Fc-engineered mAbs in hematological cancers, highlighting the continuous advancement in mAb therapy for cancer treatment.
Tags: drug delivery, mammalian expression, cell culture, downstream, immunotherapy, clinical trials, monoclonal antibodies, yeast
Read more on pmc.ncbi.nlm.nih.gov